Table 1.

CMD cytokine study characteristics and patient demographics.

Reference	Number of patients	Study type	Article location	Mean age (years)	Patient characteristics	Primary and secondary goal of study
Graetz et al. (10)	24	Prospective observational	Manuscript	50 years (range: 43.5–62 years)	aSAH	Primary: to evaluate the pattern of IL-6 expression in CMD, CSF, and serum
					Admission WFNS: I–III in 14 IV–V in 10
					Mean Fisher CT Score: 4 (range: 3–4)	Secondary: compare IL-6 expression to ICP, CMD-defined ischemia (LPR > 30, glycerol > 80 μmol/L), and outcome
					Aneurysm location ICA/MCA = 5/13 ACA/PComm = 3/3
Hanafy et al. (11)*	14	Prospective observational	Manuscript	48 years (range: 34–59 years)	aSAH	Primary: to measure CMD TNF-a post-aSAH
					Admission WFNS: IV in 1 V in 13	Secondary: to determine if clinical characteristics predict CMD TNF-a levels
					Aneurysm locations:
					ICA (4); MCA (3); ACA (6); VA (1)
Hanafy et al. (12)*	10	Retrospective case series	Manuscript	45.5 years (range: 27–65 years)	aSAH	Primary: to determine the correlation between CMD TNF-a and radiographic vasospasm as per CTA/DSA
					Admission H + H: 2 in 1 3 in 1 4 in 3 5 in 5
					Fisher CT:	Secondary: none mentioned
					Median = 3 (range: 2–4)
					Aneurysm locations: AComm (3); ICA (3); MCA (2); PCA (1); VA (1)
Helbok et al. (13)	26	Prospective observational	Manuscript	55 years (range: 47–67 years)	aSAH	Primary: to measure CMD IL-6 and CMD MMP-9 and determine the relationship to outcome
					Admission H + H: 2 in 2 3 in 6 4 in 2 5 in 16	Secondary: to determine the temporal course of IL-6 post-aSAH
					Aneurysm location: unclear locations
Mellergård et al. (14)	21 with aSAH (38 total in study with mixed pathology)	Prospective observational	Manuscript	Unknown	aSAH	Primary: to evaluate CMD cytokine profiles immediately after insertion of the CMD catheter
					No specifics on clinical status or aneurysms	Secondary: none mentioned
Mellergård et al. (15)*	88 with aSAH (Total 145 patients with mixed pathology)	Retrospective case series	Manuscript	Unknown	aSAH	Primary: to determine the CMD cytokine responds to aSAH
					No specifics on clinical status or aneurysms	Secondary: none mentioned
Mellergård et al. (16)*	88 with aSAH (total 145 patients with mixed pathology)	Retrospective case series	Manuscript	Unknown	aSAH	Primary: to determine the CMD cytokine response to aSAH
					No specifics on clinical status or aneurysms	Secondary: none mentioned
Sarrafzadeh et al. (17)	38	Prospective observational	Manuscript	53.1 years (range: unknown)	aSAH—29% with acute focal deficits on admission	Primary: to measure CMD, CSF and serum IL-6 post-aSAH
					Admission WFNS scores: I in 12 II in 7 III in 3 IV in 7 V in 9
					Mean Fisher CT score = 4	Secondary: correlate to clinical course
					Aneurysm locations: no specific given
Schiefecker et al. (18)	25	Prospective observational	Manuscript	Unknown	aSAH—poor grade	Primary: to evaluate CMD IL-6 levels post-aSAH and determine the association DIND and outcome at 3 months
						Secondary: determine probe relationship to IL-6 expression

*Studies from the same Authors and Center – there may be duplicated patient information.

aSAH, aneurysmal subarachnoid hemorrhage; H + H, Hunt and Hess; WFNS, World Federation of Neurological Surgeons; CT, computed tomography; AComm, anterior communicating artery; PComm, posterior communicating artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; ICA, internal cerebral artery; VA, vertebral artery; VBA, vertebrobasilar; PICA, posterior inferior cerebellar artery; CMD, cerebral microdialysis; CSF, cerebrospinal fluid; ICP, intracranial pressure; LPR, lactate:pyruvate ratio; IL, interleukin; MABP, mean arterial blood pressure; DC, decompressive craniectomy; DIND, delayed ischemic neurological deficit; PCA, principle component analysis.